TGFB1 and cancer: A growing number of preclinical and clinical studies have been already using drugs targeting the TGF-β signaling pathway, including anti-ligand antisense oligonucleotides, antibodies targeting ligands or receptors, and targeting TGF-β-receptor kinase drugs, especially in end-stage cancers [20–24].